Skip to main content
. 2024 Oct 2;82(10):s00441791202. doi: 10.1055/s-0044-1791202

Figure 2.

Figure 2

Note: *In the case of ofatumumab and ocrelizumab, one possibility for monitoring would be confirming B cell levels. Disease modifying therapies in family planning.